To date, no drug targeting GPIbα has been successfully developed, despite favorable arguments supporting such an approach19–21, as outlined above, in particular, the likely selective advantage of a GPIbα antagonist in conditions involving arterial thrombosis. Here, GP1BA is linked to Arterial thrombosis.